1. Indications:

Trombola (Eltrombopag) 50 mg is indicated for the treatment of:

• Thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy.
• Thrombocytopenia in pediatric patients aged 1 year and older with chronic immune thrombocytopenia (ITP) who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy.
• Severe aplastic anemia (SAA) in adult and pediatric patients aged 2 years and older who have had an insufficient response to immunosuppressive therapy.

2. Pharmacology:

Trombola (Eltrombopag) 50 mg exerts its pharmacological effects by binding to and activating the thrombopoietin receptor (c-Mpl) on megakaryocytes, stimulating their proliferation and differentiation. This leads to an increase in the production of platelets from the bone marrow, thereby raising platelet counts in the blood.

3. Dosage and Administration:

The recommended dosage of Trombola (Eltrombopag) 50 mg may vary depending on the underlying condition being treated, patient characteristics, and individual response to treatment. Typically, the prescribed dose is 50 mg taken orally once daily, with or without food. Treatment duration may vary based on the response to therapy and the discretion of the treating healthcare provider.

4. Interaction:

Trombola (Eltrombopag) 50 mg may interact with other medications, including:

• Antacids, calcium supplements, or iron supplements: Concurrent use of these agents may reduce the absorption of Eltrombopag, potentially reducing its efficacy.
• Drugs that are substrates of organic anion transporting polypeptide 1B1 (OATP1B1): Co-administration with OATP1B1 substrates may increase the plasma concentration of Eltrombopag.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Trombola (Eltrombopag) 50 mg may include:

• Headache
• Nausea
• Diarrhea
• Upper respiratory tract infection
• Increased liver enzymes
• Fatigue

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Trombola (Eltrombopag) 50 mg, patients should be aware of the following precautions:

• Hepatotoxicity, including liver function abnormalities, has been reported with Eltrombopag. Liver function tests should be performed before starting treatment and periodically thereafter.
• Thrombotic events, including portal vein thrombosis, have been reported with Eltrombopag. Patients should be monitored for signs and symptoms of thrombosis during treatment.
• Eltrombopag may increase the risk of hematologic malignancies. The benefit of treatment with Eltrombopag should be weighed against the potential risk of malignancy.

7. Overdose Effects:

In case of overdose with Trombola (Eltrombopag) 50 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Eltrombopag overdose, and patients should seek immediate medical attention if overdose is suspected.